Dianthus Therapeutics (DNTH) EBT Margin: 2022-2025
Historic EBT Margin for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to -9,250.00%.
- Dianthus Therapeutics' EBT Margin fell 807804.00% to -9,250.00% in Q3 2025 from the same period last year, while for Sep 2025 it was -4,076.22%, marking a year-over-year decrease of 281877.00%. This contributed to the annual value of -1,355.24% for FY2024, which is 18086.00% up from last year.
- As of Q3 2025, Dianthus Therapeutics' EBT Margin stood at -9,250.00%, which was up 43.37% from -16,333.68% recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' EBT Margin ranged from a high of -668.20% in Q3 2022 and a low of -16,333.68% during Q2 2025.
- Its 3-year average for EBT Margin is -3,679.31%, with a median of -1,594.37% in 2023.
- In the last 5 years, Dianthus Therapeutics' EBT Margin soared by 42,241bps in 2024 and then slumped by 1,539,455bps in 2025.
- Over the past 4 years, Dianthus Therapeutics' EBT Margin (Quarterly) stood at -855.57% in 2022, then crashed by 161,203bps to -2,467.61% in 2023, then spiked by 36,157bps to -2,106.03% in 2024, then plummeted by 807,804bps to -9,250.00% in 2025.
- Its EBT Margin was -9,250.00% in Q3 2025, compared to -16,333.68% in Q2 2025 and -2,526.74% in Q1 2025.